Unknown

Dataset Information

0

PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy.


ABSTRACT: PURPOSE:PIK3CA, encoding for subunit p110a of phosphatidylinositol 3 kinase, is frequently mutated in breast cancer. PIK3CA mutation was predictive for pathological complete response (pCR) in human epidermal growth factor 2 positive breast cancer. This study explores the association of PIK3CA mutation and pCR in triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy. Materials and Methods:A total of 92 patients with TNBC derived from a prospectively randomized phase II trial GeparSixto study (NCT01426880). Exon 9 and exon 20 of PIK3CA mutations were evaluated by using classical Sanger method with formalin-fixed paraffin-embedded tumor tissues. RESULTS:Seven of 90 tumors (7.8%) were detectable with a PIK3CA H1047R mutation. Overall, PIK3CA H1047R mutation was significantly associated with a lower pCR rate (14.3% vs. 56.6%; odds ratio, 0.128; 95% confidence interval [CI], 0.015 to 1.108; p=0.047). In carboplatin- containing treatment patients, H1047R mutation trended to predict a lower pCR rate (20% vs. 62.5%; p=0.146). In a multivariable analysis, H1047R mutation trended to predict a lower pCR rate (hazard ratio, 0.1; 95% CI, 0.01 to 1; p=0.056). CONCLUSION:TNBC with a PIK3CA H1047R mutation was less likely to achieve pCR after anthracycline-based neoadjuvant chemotherapy. Development of H1047R mutant selective inhibitors might be helpful to conquer this subtype of breast cancer.

SUBMITTER: Guo S 

PROVIDER: S-EPMC7373870 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy.

Guo Sanxing S   Loibl Sibylle S   von Minckwitz Gunter G   Darb-Esfahani Silvia S   Lederer Bianca B   Denkert Carsten C  

Cancer research and treatment 20200204 3


<h4>Purpose</h4>PIK3CA, encoding for subunit p110a of phosphatidylinositol 3 kinase, is frequently mutated in breast cancer. PIK3CA mutation was predictive for pathological complete response (pCR) in human epidermal growth factor 2 positive breast cancer. This study explores the association of PIK3CA mutation and pCR in triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy.<h4>Materials and methods</h4>A total of 92 patients with TNBC derived from a prospectively randomized  ...[more]

Similar Datasets

2007-11-23 | GSE6861 | GEO
| S-EPMC5356512 | biostudies-literature
2011-05-11 | E-GEOD-25066 | biostudies-arrayexpress
2011-05-11 | GSE25066 | GEO
| S-EPMC6685628 | biostudies-literature
| S-EPMC8763743 | biostudies-literature
| S-ECPF-GEOD-25055 | biostudies-other
| S-ECPF-GEOD-25065 | biostudies-other
2011-05-11 | E-GEOD-25065 | biostudies-arrayexpress
2011-05-11 | E-GEOD-25055 | biostudies-arrayexpress